Key Decisions and Approvals

1. Audited Financial Results: The Board approved the Audited Financial Results for the quarter and financial year ended March 31, 2026. The statutory auditors, M/s Ayyadevara & Co., Chartered Accountants, issued an unmodified opinion on these results. The results were reviewed by the Audit Committee and are available on the company's website (www.godavaridrugs.com).

2. Appointment of Internal Auditors: Based on the Audit Committee's recommendation, the Board appointed M/s. S.K. Lahoti Associates, Chartered Accountants, as Internal Auditors for the financial year 2026-27.

3. Appointment of Cost Auditors: Based on the Audit Committee's recommendation, the Board appointed M/S. Bharathula & Associates, Practicing Cost Accountants (Firm Registration No. 101019), as Cost Auditors for the financial year 2026-27. The remuneration is subject to ratification by shareholders at the ensuing Annual General Meeting.

4. 38th Annual General Meeting (AGM): The Board approved convening the 38th AGM on Friday, September 25, 2026, at 03:00 p.m. through Video-Conferencing (VC)/Other Audio Visual Means (OAVM).

Financial Results Highlights (Rupees in Lakhs)

Quarter Ended March 31, 2026 (Audited) vs. Comparable Periods:

  • Revenue from operations: ₹3,316.31 (Q4 FY26) vs. ₹2,550.26 (Q4 FY25)
  • Other Income: ₹14.12 (Q4 FY26) vs. ₹10.51 (Q4 FY25)
  • Total Revenue: ₹3,330.43 (Q4 FY26) vs. ₹2,560.77 (Q4 FY25)
  • Profit before tax: ₹161.76 (Q4 FY26) vs. ₹143.98 (Q4 FY25)
  • Net Profit for the period: ₹129.08 (Q4 FY26) vs. ₹89.31 (Q4 FY25)
  • Basic EPS: ₹1.71 (Q4 FY26) vs. ₹1.19 (Q4 FY25)
  • Diluted EPS: ₹1.64 (Q4 FY26) vs. ₹1.19 (Q4 FY25)

Financial Year Ended March 31, 2026 (Audited) vs. FY25:

  • Revenue from operations: ₹10,580.81 (FY26) vs. ₹11,335.01 (FY25)
  • Other Income: ₹80.51 (FY26) vs. ₹97.72 (FY25)
  • Total Revenue: ₹10,661.32 (FY26) vs. ₹11,432.73 (FY25)
  • Profit before tax: ₹506.30 (FY26) vs. ₹562.54 (FY25)
  • Net Profit for the year: ₹408.91 (FY26) vs. ₹438.00 (FY25)
  • Basic EPS: ₹5.43 (FY26) vs. ₹5.82 (FY25)
  • Diluted EPS: ₹5.36 (FY26) vs. ₹5.82 (FY25)

Balance Sheet Highlights (as of March 31, 2026, Audited):

  • Paid-up equity share capital (Face Value ₹10/- per share): ₹1,012.74 lakh
  • Other Equity: ₹6,042.04 lakh
  • Total Assets: ₹20,043.13 lakh
  • Total Financial Indebtedness: ₹0 (as disclosed in the default statement)

Cash Flow Statement (Year Ended March 31, 2026, Audited):

  • Net cash from operating activities: ₹73.36 lakh
  • Net cash used in investing activities: ₹(2,594.80) lakh
  • Net cash from financing activities: ₹3,735.04 lakh
  • Net increase in cash and cash equivalents: ₹1,213.60 lakh
  • Cash and cash equivalents at end of period: ₹1,450.93 lakh

Capital Structure Impact

During March 2026, the company completed a preferential allotment of 25,96,935 equity shares of ₹10 each at a premium of ₹79 per share. This increased the total number of shares from 75,30,500 to 1,01,27,435. The diluted EPS for the period was calculated based on the post-allotment number of shares.

Compliance and Regulatory Statements

1. Declaration under Regulation 33(3)(d): Mr. Mohit Jaju, Whole-time Director, declared that the statutory auditors issued an unmodified opinion on the financial results and confirmed no false or misleading statements.

2. Statement on Deviation/Variation of Funds: The company confirmed no deviation or variation in the utilization of proceeds from the preferential issue raised on March 18, 2026 (amount raised: ₹4,411.73 lakh). The funds were intended for capital expenditure towards manufacturing Active Pharmaceutical Ingredients and intermediates.

3. Outstanding Default on Loans and Debt Securities: The company confirmed no defaults on loans or debt securities during the quarter ended March 31, 2026. Total financial indebtedness was reported as ₹0.

4. Related Party Transactions: Disclosure of related party transactions for the reporting period was provided, with a total transaction value of ₹376.32 lakh. Key transactions included rents, salaries, interest received, and loans to directors and their relatives.

Additional Information

  • The financial results were prepared in accordance with Indian Accounting Standards (Ind AS).
  • The format complies with SEBI Circulars dated November 30, 2015, and July 5, 2016.
  • Corresponding figures from previous periods have been regrouped where necessary.